Comparative Pharmacology
Head-to-head clinical analysis: CYTOSAR U versus FLOXURIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTOSAR U versus FLOXURIDINE.
CYTOSAR-U vs FLOXURIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cytarabine is an antimetabolite that inhibits DNA synthesis by competing with cytidine for incorporation into DNA, causing chain termination and inhibiting DNA polymerase.
FLOXURIDINE is an antimetabolite that inhibits thymidylate synthetase, thereby blocking DNA synthesis. It is converted to 5-fluorouracil (5-FU) in the body, which is further metabolized to active nucleotides that incorporate into RNA and inhibit thymidylate synthase.
Cytarabine 100-200 mg/m² IV continuous infusion over 24 hours for 5-7 days (induction) or 1-3 g/m² IV every 12 hours for 6 doses (high-dose cytarabine).
0.1 to 0.6 mg/kg/day via continuous intra-arterial infusion for 14 days, then 7-day rest; typical dose 0.3 mg/kg/day.
None Documented
None Documented
Clinical Note
moderateFloxuridine + Digoxin
"Floxuridine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFloxuridine + Digitoxin
"Floxuridine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFloxuridine + Deslanoside
"Floxuridine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateFloxuridine + Acetyldigitoxin
"Floxuridine may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life of cytarabine is 1-3 hours for the initial phase (alpha) and 2-6 hours for the terminal phase (beta), with a mean of approximately 2.5 hours. In patients with renal impairment, half-life may be prolonged up to 6-8 hours, requiring dose adjustment.
Terminal half-life is approximately 20 minutes; clinical context: rapid clearance necessitates continuous IV infusion for sustained antineoplastic effect.
Cytosar-U (cytarabine) is primarily excreted renally as inactive metabolite uracil arabinoside (Ara-U). Approximately 70-80% of a dose is recovered in urine within 24-48 hours, with <10% excreted as unchanged drug. Biliary/fecal elimination is minimal (<5%).
Primarily hepatic metabolism to inactive metabolites; renal excretion accounts for <10% of unchanged drug; biliary/fecal excretion is minor.
Category C
Category C
Antineoplastic Antimetabolite
Antineoplastic Antimetabolite